Digital Biomarkers Market (2026-2036)
The global digital biomarkers market was valued at USD 7.6 billion in 2025. This market is expected to reach USD 34.6 billion by 2036 from an estimated USD 9.8 billion in 2026, growing at a CAGR of 13.4% during the forecast period 2026-2036.
- Published
- May 2026
- Pages
- 265
- Format
- PDF + Excel
- Report ID
- MRHC - 1041981
- Base year
- 2025
- 2025 · BASELINE
- $7.60B
- 2036
- $34.60B
- CAGR 2026–2036
- 13.4%
2025 baseline · 2026–2036 forecast at 13.4% CAGR · hover a bar for the value
Key highlights
The global digital biomarkers market is projected to reach USD 34.6 billion by 2036.
The market is expected to grow at a CAGR of 13.4% during the forecast period 2026-2036.
The global market for digital biomarkers was valued at USD 7.6 billion in 2025 and is estimated to reach USD 9.8 billion in 2026.
North America is expected to dominate the global digital biomarkers market with the largest market share in 2026, while Asia-Pacific is projected to register the highest CAGR during the forecast period.
By biomarker type, the physiological biomarkers segment is expected to hold the largest share of the market in 2026, while the behavioral biomarkers segment is projected to register the highest CAGR during the forecast period.
By data source and device type, the wearable devices segment is expected to hold the largest share in 2026, while the implantable devices segment is projected to register the highest CAGR during the forecast period.
By technology, the AI and machine learning segment is expected to hold the largest share in 2026, while the IoT-enabled platforms segment is projected to register the highest CAGR during the forecast period.
By application, the clinical trials segment is expected to hold the largest share in 2026, while the remote patient monitoring segment is projected to register the highest CAGR during the forecast period.
By end user, the pharmaceutical and biotechnology companies segment is expected to hold the largest share in 2026, while the healthcare providers segment is projected to register the highest CAGR during the forecast period.
Report summary
| Particulars | Details |
|---|---|
| Market Size by 2036 | USD 34.6 Billion |
| Market Size in 2026 | USD 9.8 Billion |
| Market Size in 2025 | USD 7.6 Billion |
| Revenue Growth Rate (2026-2036) | CAGR of 13.4% |
| Format | PDF, Excel & Cloud Portal · 265 pages |
| Dominating Biomarker Type | Physiological Biomarkers |
| Fastest Growing Biomarker Type | Behavioral Biomarkers |
| Dominating Data Source / Device Type | Wearable Devices |
| Fastest Growing Data Source / Device Type | Implantable Devices |
| Dominating Technology | AI & Machine Learning |
| Fastest Growing Technology | IoT-enabled Platforms |
| Dominating Application | Clinical Trials |
| Fastest Growing Application | Remote Patient Monitoring |
| Dominating End User | Pharmaceutical & Biotechnology Companies |
| Fastest Growing End User | Healthcare Providers |
| Dominating Geography | North America |
| Fastest Growing Geography | Asia-Pacific |
| Base Year | 2025 |
| Forecast Period | 2026 to 2036 |
Report overview
Segments covered: biomarker type, data source / device type, end user-.
According to the FDA’s 2025 reporting on digital health and translational science, submissions and clinical development activities involving wearable and digital biomarker data are increasing, reflecting the transition of digital biomarkers from research tools toward more routine clinical-trial measurement methods.
Digital biomarkers are physiological, behavioral, or biochemical measures derived from digital devices including wearable sensors, smartphones, implantable monitors, and remote monitoring systems that can objectively and continuously quantify health and disease states. Unlike conventional biomarkers that require laboratory analysis of biological specimens collected at discrete time points, digital biomarkers are captured passively and continuously from the patient's daily environment, providing a richer temporal picture of disease activity and treatment response that point-in-time measurements cannot deliver. A digital biomarker might be the six-minute walk test score calculated by an accelerometer in a heart failure patient's smartwatch, the tremor frequency and amplitude measured by a gyroscope in a Parkinson's disease patient's smartphone, the sleep efficiency and architecture derived from a continuous wristband sensor in a clinical trial for an insomnia treatment, or the irregular cardiac rhythm pattern detected by the single-lead ECG in an Apple Watch that triggers a notification for potential atrial fibrillation.
The market is growing because the pharmaceutical industry, healthcare providers, and regulators are collectively recognizing that digital biomarkers can solve the most persistent and costly problem in clinical drug development: the inability to measure disease status and treatment response accurately, continuously, and objectively outside of clinic visits. According to the Tufts Center for the Study of Drug Development's 2025 analysis, patient burden from clinic visits accounts for a large fraction of clinical trial dropout rates, and digital biomarker-based endpoints that can be assessed at home rather than at a clinic site reduce this burden while simultaneously increasing the density and objectivity of the outcome data collected. According to IQVIA’s Digital Health Trends reporting, digital biomarker and wearable-based measures are gaining broader acceptance in clinical development, reflecting a steadily growing regulatory and commercial role for digital health tools.
Two commercial catalysts are particularly significant. Apple's health research platform has enabled pharmaceutical companies to conduct research involving Apple Watch-collected digital biomarkers in large populations, with several published studies demonstrating that consumer wearables can generate research-grade digital biomarker data. According to Apple's 2025 Health Research publications, studies using Apple Watch-collected data including the Apple Heart Study have enrolled hundreds of thousands of participants at a scale that was impossible with conventional clinic-based data collection, providing enormous datasets for digital biomarker validation. Simultaneously, the FDA's September 2023 guidance on digital health technologies for remote data acquisition in clinical investigations provided regulatory clarity on how FDA evaluates wearable-collected data, removing the uncertainty that had previously slowed pharmaceutical company adoption of digital biomarker endpoints in pivotal trials.
Report infographic
Market dynamics
7 factors across 3 forcesIncreasing Adoption of Wearables & Remote Monitoring
The expanding adoption of health-focused wearable devices is creating a robust hardware foundation for the deployment of digital biomarkers at scale. Devices such as smartwatches, continuous glucose monitors, and connected physiological sensors are increasingly integrated into everyday healthcare and wellness management, enabling continuous, real-time data collection outside traditional clinical settings. Platforms like the Apple Watch and FreeStyle Libre illustrate how wearable technologies are evolving into clinically relevant tools capable of supporting both disease management and research applications.
At the same time, the rapid expansion of remote patient monitoring programs is accelerating the clinical integration of wearable-derived data. Healthcare providers are increasingly leveraging these technologies to track patient conditions such as cardiac and respiratory health in real-world environments, improving both care continuity and early intervention capabilities. Insights from organizations such as American Hospital Association highlight the growing role of wearable-enabled monitoring in modern care delivery. Collectively, these trends are driving demand for digital biomarker platforms and reinforcing the role of wearables as a key enabler of decentralized and data-driven healthcare models.
Growth in Digital Clinical Trials
The integration of digital biomarkers into clinical trials is accelerating, reflecting growing industry confidence in their ability to enhance data collection and patient-centric study design. Insights from IQVIA indicate a clear increase in the number of trials incorporating digital biomarker endpoints, highlighting their expanding role in modern clinical development. At the same time, the U.S. Food and Drug Administration Digital Health Center of Excellence has reported rising engagement from sponsors seeking regulatory guidance on digital endpoints, underscoring the importance of regulatory clarity in supporting adoption.
Research from Tufts Center for the Study of Drug Development demonstrates that digital clinical outcome assessments can reduce patient burden compared to traditional site-based evaluations, helping to address one of the key contributors to trial dropout. In parallel, findings from Veeva Systems highlight the rapid growth in the integration of wearable and sensor-generated data into clinical trial platforms. Together, these trends reflect a broader shift toward decentralized, data-rich clinical trials, where digital biomarkers play a central role in improving efficiency, patient engagement, and data quality.
Table of contents
13 chapters · 156 sections · 265 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Biomarker Type | Physiological Biomarkers | Behavioral biomarkers |
| By Data Source / Device Type | Wearable Devices | Implantable devices |
| By Technology | AI & Machine Learning | IoT-enabled platforms |
| By Application | Clinical Trials | Remote patient monitoring |
| By End User | Pharmaceutical & Biotechnology Companies | Healthcare providers |
By Biomarker Type
- Physiological Biomarkers to Hold the Largest Share
- The physiological biomarkers segment is expected to account for the largest share of the global digital biomarkers market.
- Physiological digital biomarkers including heart rate, heart rate variability, SpO2, ECG-derived metrics, step count, and gait parameters are the most commercially established and most widely validated category, measured by the very large installed base of consumer wearables including Apple Watch and Fitbit as well as clinical-grade devices from ActiGraph, Empatica, and AliveCor.
- Abbott's FreeStyle Libre CGM representing continuous glucose physiological biomarker data in approximately USD 5.7 billion annual revenues per its 2025 annual report illustrates the commercial scale of this segment.
- However, the behavioral biomarkers segment is projected to register the highest CAGR during the forecast period.
- Behavioral digital biomarkers derived from passive smartphone and wearable data are emerging as uniquely sensitive indicators of neurological and psychiatric disease status with clinical validation evidence growing rapidly.
- The Lancet Digital Health 2025 meta-analysis confirming passive smartphone behavioral biomarkers' clinical utility for depression, combined with the growing Biogen and Roche clinical programs using behavioral digital endpoints, are creating the evidence base for a fast-growing new biomarker category that is particularly compelling for CNS drug development where objective continuous measurement has historically been almost impossible.
By Data Source / Device Type
- Wearable Devices to Hold the Largest Share
- The wearable devices segment is expected to account for the largest share of the global digital biomarkers market.
- The very large global installed base of health wearables provides the hardware foundation for wearable digital biomarker deployment at population scale.
- Apple Watch, Garmin, and Fitbit collectively represent the dominant consumer wearable platforms, while ActiGraph and Empatica provide research-grade wearable digital biomarker solutions with FDA-reviewed credentials for use in clinical trials.
- However, the implantable devices segment is projected to register the highest CAGR during the forecast period.
- Implantable cardiac monitors including Medtronic's Reveal LINQ, which continuously records cardiac rhythms and wirelessly transmits data to a clinician monitoring center, represent a high-value clinical digital biomarker platform for arrhythmia detection and cardiac monitoring in implant-grade patients.
- Abbott's implantable CGM development program targeting sensors with multi-year implant durations for continuous glucose digital biomarker data represents the next frontier of implantable metabolic monitoring.
- As implant procedures become less invasive and device longevity increases, the implantable digital biomarker segment is expected to grow rapidly from its currently smaller base.
By Technology
- AI & Machine Learning to Hold the Largest Share
- The AI and machine learning segment is expected to account for the largest share of the global digital biomarkers market.
- AI algorithms are the foundational enabler of digital biomarker utility: without sophisticated machine learning models to extract clinically meaningful signals from high-dimensional, high-frequency sensor data streams, the raw sensor data would be too noisy, too voluminous, and too complex to interpret clinically.
- Apple's atrial fibrillation detection algorithm in Apple Watch, AliveCor's FDA-cleared AI arrhythmia detection, and Biogen's behavioral biomarker algorithms are all AI-based digital biomarker implementations generating commercially deployed clinical value.
- However, the IoT-enabled platforms segment is projected to register the highest CAGR during the forecast period.
- The growing ecosystem of Internet of Things-connected medical devices, home monitoring sensors, and connected health platforms is creating the integration infrastructure through which multiple digital biomarker streams from different devices can be consolidated, transmitted securely, and made available to clinical monitoring platforms in near-real-time.
- The maturation of IoT connectivity standards, cloud API frameworks, and device interoperability protocols is progressively lowering the integration cost and complexity of multi-device digital biomarker deployments in clinical and home settings.
By Application
- Clinical Trials to Hold the Largest Share
- The clinical trials application segment, which is labeled as the largest segment in the original TOC, is expected to account for the largest share of the global digital biomarkers market.
- Pharmaceutical companies are the highest-spending adopters of digital biomarker technology, integrating wearable endpoints and remote monitoring into clinical trial protocols to improve endpoint sensitivity, reduce patient burden, and generate richer and more continuous outcome data.
- However, the remote patient monitoring segment is projected to register the highest CAGR during the forecast period.
- The sustained expansion of remote patient monitoring programs enabled by telehealth reimbursement infrastructure, combined with the growing availability of FDA-cleared wearable devices generating clinical-grade digital biomarker data, is creating a rapidly expanding commercial market for digital biomarker-based RPM.
- According to the American Hospital Association's 2025 data, RPM programs incorporating digital biomarker-equipped wearables demonstrated improved clinical outcomes and reduced hospital readmissions in multiple published studies, creating the clinical evidence that is driving payer coverage and hospital system investment.
By End User
- Pharmaceutical & Biotechnology Companies to Hold the Largest Share
- The pharmaceutical and biotechnology companies segment is expected to account for the largest share of the global digital biomarkers market.
- Large pharmaceutical companies including Biogen, Roche, Novartis, and Sanofi are investing in proprietary digital biomarker programs as competitive differentiators in drug development, recognizing that superior endpoint sensitivity from validated digital biomarkers can reduce required trial sample sizes, shorten trial duration, and provide more compelling regulatory submission packages.
- However, the healthcare providers segment is projected to register the highest CAGR during the forecast period.
- Hospital systems and health networks are rapidly deploying digital biomarker-based remote patient monitoring programs for chronic disease management, post-discharge cardiac monitoring, and diabetes management, driven by both clinical evidence of improved outcomes and reimbursement support from CMS.
- According to CMS's 2025 Remote Patient Monitoring reimbursement data, RPM program reimbursement grew at above-average rates in 2024 as more healthcare provider organizations deployed FDA-cleared wearable digital biomarker monitoring programs for their chronic disease patient populations.
Geographic analysis
North America
Largest shareIn 2026, North America is expected to account for the largest share of the global digital biomarkers market. The United States leads this market due to its concentration of advanced digital health and biomarker technology companies, including Apple, Alphabet, AliveCor, ActiGraph, Biofourmis, and Empatica. The region also benefits from strong pharmaceutical R&D investment and early adoption of digital endpoints within clinical trials, reflecting a broader shift toward data-driven and patient-centric development models. Supportive regulatory and reimbursement frameworks further reinforce North America’s leadership. The U.S. Food and Drug Administration Digital Health Center of Excellence has reported increasing engagement from sponsors around digital biomarker endpoints, highlighting growing integration into clinical development. In parallel, commercially established platforms such as FreeStyle Libre demonstrate the real-world scalability of digital biomarker technologies. Additionally, reimbursement expansion by the Centers for Medicare & Medicaid Services for remote patient monitoring is enabling broader provider adoption of wearable-based monitoring solutions, further accelerating market growth in the region.
Asia-Pacific
Fastest growthHowever, the Asia-Pacific digital biomarkers market is expected to grow at the fastest rate during the forecast period. The region combines a large and expanding population of patients with chronic diseases with rapidly advancing digital health infrastructure and high smartphone penetration, enabling widespread adoption of digital biomarker solutions. Countries across the region are increasingly leveraging connected devices and mobile health platforms to support continuous monitoring and data-driven disease management, creating strong demand for scalable digital biomarker technologies. Government-led initiatives are playing a central role in accelerating this growth. For example, China’s Healthy China 2030 strategy emphasizes the use of digital health tools for chronic disease management, while Japan’s rapidly aging population is driving demand for remote monitoring of age-related conditions. South Korea further strengthens the regional landscape through its advanced digital health ecosystem and platforms developed by companies such as Samsung. Collectively, these factors—along with growing adoption of connected health devices across the region—are positioning Asia-Pacific as the fastest-growing market for digital biomarkers.
Europe
Europe is a large and technically sophisticated market for digital biomarkers, with strong pharmaceutical company investment through Roche, Novartis, and Boehringer Ingelheim's digital biomarker programs and an active regulatory environment from the EMA that is progressively developing frameworks for digital health endpoint assessment. The UK's NHS digital strategy and its digital biomarker research programs at major academic medical centers are generating valuable digital biomarker validation data. Germany's Digital Healthcare Act creating reimbursement for digital health applications supports the commercial deployment of digital biomarker-based monitoring tools. Switzerland hosts Roche and Novartis, both of which have significant digital biomarker research programs, and the European femtech and digital health startup ecosystem is generating innovative new digital biomarker applications.
Competitive landscape
- Apple Inc. (U.S.)
- Alphabet Inc. (U.S.)
- Fitbit/Google (U.S.)
- Garmin Ltd. (Switzerland/U.S.)
- Empatica Inc. (U.S./Italy)
- ActiGraph LLC (U.S.)
- Biofourmis (U.S.)
- AliveCor Inc. (U.S.)
- Philips Healthcare · Netherlands
- Medtronic plc · Ireland
- Abbott Laboratories (U.S.)
- Biogen Inc. (U.S.)
- Roche Holding AG · Switzerland
- Novartis AG · Switzerland
- Sanofi · France
Frequently asked questions
The global digital biomarkers market is expected to reach USD 34.6 billion by 2036 from an estimated USD 9.8 billion in 2026, at a CAGR of 13.4% during the forecast period 2026-2036.
Cite this report
Meticulous Research. (2026). Digital Biomarkers Market - Global Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MRHC - 1041981). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/digital-biomarkers-market-6664